Search

Ionis Pharmaceuticals Inc

Gesloten

SectorGezondheidszorg

56.55 3.91

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

53.84

Max

55.23

Belangrijke statistieken

By Trading Economics

Inkomsten

-22M

-115M

Verkoop

22M

268M

EPS

-0.7

Winstmarge

-42.787

Werknemers

1,480

EBITDA

-37M

-105M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+66.32% upside

Dividenden

By Acuity

Volgende Winsten

28 okt 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-193M

9.1B

Vorige openingsprijs

52.64

Vorige sluitingsprijs

56.55

Nieuwssentiment

By Acuity

100%

0%

329 / 340 Rangschikking in Healthcare

Ionis Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

6 aug 2026, 20:03 UTC

Macro Event

Ionis Pharmaceuticals Inc shares are higher, supported by high trading volume, though they remain below their 20-day moving average and near a one-month low.

5 aug 2026, 23:56 UTC

Ionis Pharmaceuticals shares are lower in after-market hours, influenced by a disappointing ADP employment report revealing only 44,000 private sector jobs added in July.

4 aug 2026, 23:41 UTC

Ionis Pharmaceuticals Inc shares are lower in after-market hours, having reached a session low earlier. No specific news was identified to explain the movement.

3 aug 2026, 20:51 UTC

Ionis Pharmaceuticals Inc. shares are trading roughly flat in after-market hours, maintaining a cumulative return of 0.02% since Monday's close.

1 aug 2026, 00:06 UTC

Ionis Pharmaceuticals Inc shares are higher in after-market hours, recovering from recent declines amid broader market gains, including a rise in the Nikkei 225 Index.

31 jul 2026, 23:01 UTC

Ionis Pharmaceuticals Inc shares are higher in after-market hours, supported by a notable advance in the Biotechnology sub-sector. No specific news was identified.

30 jul 2026, 23:46 UTC

Ionis Pharmaceuticals shares are slightly higher in after-market hours, though no specific news explains the movement amid mixed Asian equity performance and geopolitical concerns.

29 jul 2026, 23:51 UTC

Ionis Pharmaceuticals Inc is trading lower in after-market hours, continuing a trend of four consecutive sessions below its 20-day moving average.

28 jul 2026, 18:03 UTC

News

Ionis Pharmaceuticals shares are lower amid an investigation by Bronstein, Gewirtz & Grossman and disappointing earnings forecasts projecting a loss of $1.07 per share.

27 jul 2026, 20:07 UTC

News
Social Media

Ionis Pharmaceuticals shares are lower amid an investigation into potential claims following the company's disclosure about its failed Phase-3 trial.

25 jul 2026, 00:02 UTC

Ionis Pharmaceuticals Inc shares are lower in after-market hours, diverging from recent gains. No specific news was identified to explain the decline.

24 jul 2026, 21:01 UTC

Ionis Pharmaceuticals Inc shares are lower in after-market hours, following a broader market decline driven by disappointing earnings from major companies and falling crude oil prices.

23 jul 2026, 20:03 UTC

Ionis Pharmaceuticals Inc shares are higher during Thursday's session, continuing a notable increase since Wednesday. Trading volume is unusually high today.

22 jul 2026, 22:26 UTC

Ionis Pharmaceuticals shares are slightly higher in after-market hours. Broader market conditions reflect ongoing geopolitical tensions and rising crude oil prices.

21 jul 2026, 21:01 UTC

Ionis Pharmaceuticals Inc shares are lower in after-market hours, with no specific news identified to explain the decline. The broader market is rebounding.

20 jul 2026, 23:01 UTC

Ionis Pharmaceuticals Inc shares are higher in after-market trading, recovering from earlier lows after three consecutive daily declines. No specific news was identified.

Peer Vergelijking

Prijswijziging

Ionis Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

66.32% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 90.13 USD  66.32%

Hoogste 115 USD

Laagste 68 USD

Gebaseerd op 18 Wall Street-analisten die 12-maands prijsdoelen bieden voor Ionis Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

18 ratings

15

Buy

3

Hold

0

Sell

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.
help-icon Live chat